Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission
- 325 Downloads
The proper management of pregnant women infected with hepatitis B virus (HBV) is necessary to prevent maternal and fetal morbidity and mortality and to protect the baby from HBV infection. In the majority of cases, vertical transmission can be prevented with a universal screening program, HBV vaccine immunoprophylaxis, and administration of hepatitis B immunoglobulin (HBIg) for babies born to mothers with HBV. However, in mothers with a high viral load (>200,000 or >1,000,000 IU/ml, depending on the guideline), the chance of immunoprophylaxis failure remains high. The standard recommendation is to give an antiviral agent during the third trimester in these patients. US FDA pregnancy category B agents such as tenofovir and telbivudine are allowed through all trimesters of pregnancy. Breastfeeding for patients who receive antiviral agents can be allowed after a risk–benefit discussion with the patient.
KeywordsLamivudine Tenofovir Telbivudine MTCT Prophylaxis
Compliance with Ethical Standards
Conflict of interest
Naichaya Chamroonkul has no conflicts of interest. Teerha Piratvisuth has received research grants from Geliad, MSD, and BMS and consulting fees or speakers’ honoraria from Geliad, MSD, BMS, Roche, GSK, Novatis, and Bayers.
No sources of funding were used to support the writing of this manuscript.
- 2.World Health Organization. Hepatitis B fact sheet. Geneva: WHO. 2016. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 15 July 2016.
- 32.Antiretroviral Pregnancy Registry Steering Committee. The Antiretroviral Pregnancy Registry interim report. 1 January 1989 through 31 January 2016. http://www.apregistry.com/forms/interim_report.pdf. Accessed 26 Nov 2016.
- 39.Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983;3(2):135–41.CrossRefPubMedGoogle Scholar
- 47.Centers for Disease Control and Prevention (CDC). Global routine vaccination coverage—2012. Morb Mortal Wkly Rep. 2013;62:858–61.Google Scholar
- 48.Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis B immunoglobulin: double-blind randomised placebo-controlled study. Lancet. 1984;1(8383):921–6.CrossRefPubMedGoogle Scholar
- 54.Centers for Disease Control and Prevention (CDC). Hepatitis B vaccine birthdose practices in a country where hepatitis B is endemic—Laos, December 2011–February 2012. Morb Mortal Wkly Rep. 2013;62(29):587–90.Google Scholar
- 57.Zou H, Chen Y, Duan Z, Zhang H, Pan C. A retrospective study for clinical outcome of caesarean section on perinatal transmission of hepatitis B virus in infants born to HBeAg positive mothers with chronic hepatitis B (CHB). Hepatology. 2010;52(Suppl(1)):441A.Google Scholar
- 67.Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al.; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT Study); Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV PreMIT Study. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–86.Google Scholar
- 68.Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al.; China Study Group for the Mother-to-Child Transmission of Hepatitis B. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–34.Google Scholar
- 75.World Health Organization. Hepatitis B and breastfeeding. No. 22. Geneva: WHO; 1996. http://www.who.int/child_adolescent_health/documents/pdfs/hepatitis_b_and_breastfeeding.pdf. Accessed 27 Nov 2016.